

the Credit Suisse Affiliated QPAM, with the exception of reasonable restrictions, appropriately disclosed in advance, that are specifically designed to ensure equitable treatment of all investors in a pooled fund in the event such withdrawal or termination may have adverse consequences for all other investors, provided that such restrictions are applied consistently and in like manner to all such investors; and (5) not to impose any fees, penalties, or charges for such termination or withdrawal with the exception of reasonable fees, appropriately disclosed in advance, that are specifically designed to prevent generally recognized abusive investment practices or specifically designed to ensure equitable treatment of all investors in a pooled fund in the event such withdrawal or termination may have adverse consequences for all other investors, provided that such fees are applied consistently and in like manner to all such investors. Within six (6) months of the date of publication of this notice of exemption in the **Federal Register**, each Credit Suisse Affiliated QPAM will provide a notice to such effect to each ERISA-covered plan or IRA for which a Credit Suisse Affiliated QPAM provides asset management or other discretionary fiduciary services;

(l) Each Credit Suisse Affiliated QPAM will maintain records necessary to demonstrate that the conditions of this exemption have been met for six (6) years following the date of any transaction for which such Credit Suisse Affiliated QPAM relies upon the relief in the exemption;

(m) The Credit Suisse Affiliated QPAMs provided a notice of the proposed exemption along with a separate summary describing the facts that led to the Conviction, which has been submitted to the Department, and a prominently displayed statement that the Conviction results in a failure to meet a condition in PTE 84–14 to: (1) Each sponsor of an ERISA-covered plan and each beneficial owner of an IRA invested in an investment fund managed by a Credit Suisse Affiliated QPAM, or the sponsor of an investment fund in any case where a Credit Suisse Affiliated QPAM acts only as a sub-advisor to the investment fund; (2) each entity that may be a Credit Suisse Related QPAM; and (3) each ERISA-covered plan for which the New York Branch of Credit Suisse AG provides fiduciary securities lending services; and

(n) A Credit Suisse Affiliated QPAM will not fail to meet the terms of this exemption solely because a Credit Suisse Related QPAM or a different

Credit Suisse Affiliated QPAM fails to satisfy a condition for relief under this exemption. A Credit Suisse Related QPAM will not fail to meet the terms of this exemption solely because Credit Suisse AG, a Credit Suisse Affiliated QPAM, or a different Credit Suisse Related QPAM fails to satisfy a condition for relief under this exemption;

(o) ERISA-covered plans and IRAs with assets managed by Credit Suisse Affiliated QPAMs in reliance of PTE 84–14 must receive a copy of this final exemption no later than 90 days following the date of publication in the **Federal Register**. Notice to a plan or IRA may be provided electronically (including by an email that has a link to the exemption).

Section II: Definitions

(a) The term “Credit Suisse Affiliated QPAM” means a “qualified professional asset manager” (as defined in section VI(a)¹⁴ of PTE 84–14) that relies on the relief provided by PTE 84–14 and with respect to which Credit Suisse AG is a current or future “affiliate” (as defined in section VI(d) of PTE 84–14). The term “Credit Suisse Affiliated QPAM” excludes the parent entity, Credit Suisse AG.

(b) The term “Credit Suisse Related QPAM” means any current or future “qualified professional asset manager” (as defined in section VI(a) of PTE 84–14) that relies on the relief provided by PTE 84–14, and with respect to which Credit Suisse AG owns a direct or indirect five percent or more interest, but with respect to which Credit Suisse AG is not an “affiliate” (as defined in Section VI(d) of PTE 84–14).

(c) The term “Conviction” means the judgment of conviction against Credit Suisse AG for one count of conspiracy to violate section 7206(2) of the Internal Revenue Code in violation of Title 18, United States Code, Section 371, that was entered in the District Court for the Eastern District of Virginia in Case Number 1:14-cr-188-RBS, on November 21, 2014.

¹⁴ In general terms, a QPAM is an independent fiduciary that is a bank, savings and loan association, insurance company, or investment adviser that meets certain equity or net worth requirements and other licensure requirements and that has acknowledged in a written management agreement that it is a fiduciary with respect to each plan that has retained the QPAM.

Signed at Washington, DC, this 25th day of September, 2015.

Lyssa Hall,

*Director of Exemption Determinations,
Employee Benefits Security Administration,
U.S. Department of Labor.*

[FR Doc. 2015–24919 Filed 10–1–15; 8:45 am]

BILLING CODE 4510–29–P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (15–086)]

Notice of Intent To Grant Partially Exclusive License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of intent to grant partially exclusive license.

SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant a partially-exclusive license in the United States to practice the invention described and claimed in U.S. Patent No. 7,623,972 for an invention entitled “Detection of Presence of Chemical Precursors”; U.S. Patent No. 7,801,687 for an invention entitled “Chemical Sensors Using Coated or Doped Carbon Nanotube Networks”; U.S. Patent No. 7,968,054 for an invention entitled “Nanostructure Sensing and Transmission Of Gas Data”; and U.S. Patent No. 8,000,903 for an invention entitled “Coated or Doped Carbon Nanotube Network Sensors as Affected by Environmental Parameters”; and ARC–16902–1 for an invention entitled “Nanosensors for medical diagnosis”; and ARC–16292–1 for an invention entitled “Nanosensor/Cell Phone Hybrid for Detecting Chemicals and Concentrations,” to The Medical Innovation Group, LLC, having its principal place of business at 416 Mount Airy Road, Basking Ridge, NJ 07920. The patent rights in this invention have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective partially-exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

DATES: The prospective partially exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NASA receives written objections including evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Competing applications completed and received by NASA within fifteen (15) days of the date of this published notice will also be treated as objections to the grant of the contemplated partially exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

ADDRESSES: Objections relating to the prospective license may be submitted to Patent Counsel, Office of Chief Counsel, NASA Ames Research Center, Mail Stop 202A-4, Moffett Field, CA 94035-1000. (650) 604-5104; Fax (650) 604-2767.

FOR FURTHER INFORMATION CONTACT: Robert M. Padilla, Chief Patent Counsel, Office of Chief Counsel, NASA Ames Research Center, Mail Stop 202A-4, Moffett Field, CA 94035-1000. (650) 604-5104; Fax (650) 604-2767. Information about other NASA inventions available for licensing can be found online at <http://technology.nasa.gov/>.

Mark P. Dvorscak,
Agency Counsel for Intellectual Property.
[FR Doc. 2015-24955 Filed 10-1-15; 8:45 am]

BILLING CODE 7510-13-P

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

National Endowment for the Arts

Senior Executive Service Performance Review Board

ACTION: Notice.

SUMMARY: This notice announces the membership of the National Endowment for the Arts (NEA) Senior Executive Service (SES) Performance Review Board (PRB).

DATES: *Effective Date:* September 28, 2015.

ADDRESSES: Send comments concerning this notice to: National Endowment for the Arts, 400 7th Street SW., Washington, DC 20506

FOR FURTHER INFORMATION CONTACT: Craig McCord Sr. by telephone at (202) 682-5473 or by email at mccordc@arts.gov.

SUPPLEMENTARY INFORMATION: 4314(c)(1) through (5) of title 5, U.S.C., requires each agency to establish, in accordance with regulations prescribed by the Office of Personnel Management, one or more SES Performance Review Boards. The Board shall review and evaluate the initial appraisal of a senior executive's

performance by the supervisor, along with any response by the senior executive, and make recommendations to the appointing authority relative to the performance of the senior executive.

The following persons have been selected to serve on the Performance Review Board of the National Endowment for the Arts (NEA):
Winona Varnon—Deputy Chairman for Management and Budget
Michael Griffin—Chief of Staff
Sunil Iyengar—Director, Research & Analysis

Dated: September 28, 2015.

Kathy N. Daum,

Director, Administrative Services.

[FR Doc. 2015-24963 Filed 10-1-15; 8:45 am]

BILLING CODE P

NUCLEAR REGULATORY COMMISSION

Advisory Committee on Reactor Safeguards; Notice of Meeting

In accordance with the purposes of Sections 29 and 182b of the Atomic Energy Act (42 U.S.C. 2039, 2232b), the Advisory Committee on Reactor Safeguards (ACRS) will hold a meeting on October 7-10, 2015, 11545 Rockville Pike, Rockville, Maryland.

Wednesday, October 7, 2015, Conference Room T2-B1, 11545 Rockville Pike, Rockville, Maryland

2:00 p.m.–2:05 p.m.: Opening Remarks by the ACRS Chairman (Open)—The ACRS Chairman will make opening remarks regarding the conduct of the meeting.

2:05 p.m.–3:30 p.m.: Reactor Oversight Process (ROP) Enhancements (Open)—The Committee will hear presentations by and hold discussions with representatives of the NRC staff regarding proposed enhancements to the ROP Process.

3:30 p.m.–4:00 p.m.: Assessment of the Quality of Selected Research Projects (Open)—The Committee will discuss the quality of selected NRC research projects.

4:00 p.m.–6:00 p.m.: Preparation of ACRS Reports (Open)—The Committee will discuss proposed ACRS reports on matters discussed during this meeting.

Thursday, October 8, 2015, Conference Room T2-B1, 11545 Rockville Pike, Rockville, Maryland

8:30 a.m.–8:35 a.m.: Opening remarks by the ACRS Chairman (Open)—The ACRS Chairman will make opening remarks regarding the conduct of the meeting.

8:35 a.m.–11:00 a.m.: SHINE Construction Permit Application (Open/Closed) - The Committee will hear presentations by and hold discussions with representatives of the NRC staff and SHINE regarding the safety evaluation associated with the SHINE construction permit application for a Mo99 medical radioisotope production facility under 10 CFR part 50.

Note: A portion of this meeting may be closed in order to discuss and protect information designated as proprietary pursuant to 5 U.S.C. 552b(c)(4).

1:00 p.m.–3:30 p.m.: Interim Staff Guidance (ISG): Acute Chemical Exposures and Quantitative Standards (Open)—The Committee will hear presentations by and hold discussions with representatives of the NRC staff, NEI, and other members of the public regarding the Interim Staff Guidance (ISG): Acute Chemical Exposures and Quantitative Standards.

3:30 p.m.–6:00 p.m.: Preparation of ACRS Reports (Open)—The Committee will discuss proposed ACRS reports on matters discussed during this meeting.

Note: A portion of this meeting may be closed in order to discuss and protect information designated as proprietary pursuant to 5 U.S.C. 552b(c)(4).

Friday, October 9, 2015, Conference Room T2-B1, 11545 Rockville Pike, Rockville, Maryland

8:30 a.m.–10:00 a.m.: Future ACRS Activities/Report of the Planning and Procedures Subcommittee (Open/Closed)—The Committee will discuss the recommendations of the Planning and Procedures Subcommittee regarding items proposed for consideration by the Full Committee during future ACRS Meetings, and matters related to the conduct of ACRS business, including anticipated workload and member assignments.

Note: A portion of this meeting may be closed pursuant to 5 U.S.C. 552b(c)(2) and (6) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of ACRS, and information the release of which would constitute a clearly unwarranted invasion of personal privacy.

10:00 a.m.–10:15 a.m.: Reconciliation of ACRS Comments and Recommendations (Open)—The Committee will discuss the responses from the NRC Executive Director for Operations to comments and recommendations included in recent ACRS reports and letters.

1:00 p.m.–2:00 p.m.: Meeting with Commissioner Baran (Open)—The Committee will meet with